NCT00179465Active, not recruitingPhase 3
Treating Schizophrenia by Correcting Abnormal Brain Development
Addition of Tiagabine to Second-Generation Antipsychotics in the Treatment of Recent-Onset Schizophrenia by Modification of Developmental Reorganization of the Prefrontal Cortex
Source: ClinicalTrials.gov · Last updated 27 Jan 2025
Brief summary (registry, in English)
The purpose of this study is to determine whether treatment with tiagabine (Gabitril) during the early course of schizophrenia can fundamentally correct the brain deficits associated with the disease. This study is funded by the National Institutes of Health.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 12 Sept 2005
- Start date
- Nov 2003
- Primary completion date
- Sept 2026
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Diseases
- Schizophrenia
- NCT number
- NCT00179465
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 36
- From Nov 2003 to the primary completion date, Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosis of schizoaffective disorder.
- History of seizures or any neurologic disorders.
- Known HIV infection.
- History of any substance dependence.
Other
- Has failed two or more clinically adequate antipsychotic trials.
- Pregnant or nursing women.
- Actively suicidal.
- Currently meets criteria for substance abuse/dependence.
- Other MRI exclusion criteria per Radiology Department protocols.
Who the study is looking for
- Meets criteria for the diagnosis of schizophrenia, with onset of psychotic symptoms within the past 3 years.
- Currently on second-generation antipsychotics for at least 3 months.
- Age 18-25, otherwise healthy.
Age in the registry: 18 years to 25 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beth Israel Deaconess Medical Center Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.